Breaking News Just Announced
This tiny telehealth stock is up over 50% in the past month.
Put it on your watchlist now
Ansbert Gadicke, insider at iTeos Therapeutics
Ansbert Gadicke Insider Alerts

Get notified the next time Ansbert Gadicke buys or sells iTeos Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Ansbert Gadicke Insider Information

Major Shareholder of iTeos Therapeutics
Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, as well as Managing Partner of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities managed by MPM.   He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), iTeos Therapeutics (NASDAQ: ITOS) and AlloVir (NASDAQ: ALVR). MPM believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and his co-founder Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at NextPoint Therapeutics, Orna, and TCR2 Therapeutics (NASDAQ: TCRR) and as a Board Director at Cullinan Oncology (NASDAQ: CGEM), ElevateBio and Allovir (NASDAQ: ALVR). He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

What is Ansbert Gadicke's net worth?

The estimated net worth of Ansbert Gadicke is at least $8.47 million as of September 13th, 2021. Dr. Gadicke owns 248,170 shares of iTeos Therapeutics stock worth more than $8,472,524 as of November 29th. This net worth estimate does not reflect any other investments that Dr. Gadicke may own. Learn More.

How do I contact Ansbert Gadicke?

The corporate mailing address for Dr. Gadicke and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]

Has Ansbert Gadicke been buying or selling shares of iTeos Therapeutics?

In the last ninety days, Ansbert Gadicke has sold $3,532,416.00 of iTeos Therapeutics stock. Most recently, Ansbert Gadicke sold 60,808 shares of the business's stock in a transaction on Wednesday, November 24th. The shares were sold at an average price of $36.29, for a transaction totalling $2,206,722.32.

Who are iTeos Therapeutics' active insiders?

iTeos Therapeutics' insider roster includes Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), Les Korsh (VP), and Yvonne McGrath (VP).

Are insiders buying or selling shares of iTeos Therapeutics?

During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $130,450.00. During the last year, insiders at the sold shares 38 times. They sold a total of 603,772 shares worth more than $17,993,039.06. The most recent insider tranaction occured on November, 24th when Major Shareholder Ansbert Gadicke sold 60,808 shares worth more than $2,206,722.32. Insiders at iTeos Therapeutics own 4.0 % of the company.

Information on this page was last updated on 11/24/2021.

Ansbert Gadicke Insider Trading History at iTeos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Sell60,808$36.29$2,206,722.32View SEC Filing Icon  
11/22/2021Sell35,333$37.52$1,325,694.16View SEC Filing Icon  
9/13/2021Sell35,785$27.64$989,097.40View SEC Filing Icon  
9/9/2021Sell38,028$28.97$1,101,671.16View SEC Filing Icon  
9/7/2021Sell50,996$29.18$1,488,063.28View SEC Filing Icon  
See Full Table

Ansbert Gadicke Buying and Selling Activity at iTeos Therapeutics

This chart shows Ansbert Gadicke's buying and selling at iTeos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iTeos Therapeutics Company Overview

iTeos Therapeutics logo
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $34.14
Low: $34.03
High: $35.42

50 Day Range

MA: $29.30
Low: $25.57
High: $38.22

2 Week Range

Now: $34.14
Low: $17.43
High: $47.61


2,224 shs

Average Volume

300,526 shs

Market Capitalization

$1.20 billion

P/E Ratio


Dividend Yield



Breaking News Just Announced
This tiny telehealth stock is up over 50% in the past month.
Put it on your watchlist now